Making Antibody Drug Conjugate Medicines Consistent Across Batches

This patent describes methods for precisely controlling the drug amount in antibody drug conjugate (ADC) medicines, ensuring each batch has a consistent strength and effect.

What it covers

The patent provides ways to make sure different batches of antibody drug conjugate (ADC) medicines have the same strength. It focuses on reducing "potency variability," meaning how much the drug's effect changes from one batch to another. One method (Claim 1) involves deciding on a specific amount of drug to aim for, based on a set amount of antibody and a fixed "drug antibody ratio" (DAR), then mixing the medicine to hit that target. Another detailed method (Claim 6) involves measuring the DAR, defining acceptable ranges for both antibody and drug concentrations, then calculating precise upper and lower limits for the drug concentration using a specific formula. Finally, the medicine is formulated to a drug concentration that is exactly in the middle of these calculated limits, ensuring consistency. For example, if a batch of ADC medicine needs to have a drug concentration within a tight range of 95-105 µg/mL, this method helps achieve that precise target.

What it doesn't cover

• —Does not cover methods that *only* target a specific antibody concentration without also considering drug concentration (Claim 16).
• —Does not cover methods that do not involve determining a target drug concentration (Claim 1).
• —Does not cover methods that do not use a fixed or variable drug antibody ratio (DAR) in their calculations (Claim 1, 2, 6).
• —Does not cover methods that formulate outside the specified concentration ranges, such as ±5% or ±10% of the targeted drug concentration (Claim 3, 16).
• —Does not cover methods that do not involve comparing calculated and defined drug specification limits to find effective limits (Claim 6).

The clever bit

The novelty lies in the precise mathematical methods for defining and hitting a target drug concentration, especially by integrating the drug antibody ratio (DAR) and overlapping specification ranges, rather than just focusing on antibody concentration alone. This ensures the *active drug component* is consistent, not just the antibody carrier.

Why it matters

Antibody drug conjugates (ADCs) are powerful cancer treatments, but their effectiveness can vary if batches aren't made consistently. This patent addresses a critical manufacturing challenge in the pharmaceutical industry: ensuring that every dose a patient receives has the same strength. By reducing potency variability, these methods help make ADC therapies safer and more reliable, which is essential for patient outcomes and regulatory approval.

Real-world examples

• 1.Manufacturing processes for cancer drugs like Kadcyla (trastuzumab emtansine) or Enhertu (trastuzumab deruxtecan)
• 2.Quality control for new ADC therapies in clinical trials
• 3.Production of ADCs using maytansinoid or auristatin drug components